Skip to content
Austin Top 50
Author:
Zymeworks Inc.
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
September 28, 2026
Zymeworks Completes Acquisition of Theravance Biopharma
September 23, 2026
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
August 25, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
August 11, 2026
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 6, 2026
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
July 16, 2026
Zymeworks to Acquire Theravance Biopharma, Inc.
June 29, 2026
Zymeworks Announces Participation in Upcoming Investor Conferences
May 13, 2026
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
April 23, 2026
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
April 20, 2026
1
2
Next Page
→